A comparative study of visual outcome in patients with optic neuritis treated with five or seven days of intravenous corticosteroid treatment

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorSILVA, Guilherme Diogo
dc.contributor.authorTERRIM, Sara
dc.contributor.authorFALCAO, Fernando Cavalcantide Sa e Benevides
dc.contributor.authorFALCA, Maria Alice Pimentel
dc.contributor.authorCHAVES, Cleuber Esteves
dc.contributor.authorAPOSTOLOS-PEREIRA, Samira
dc.contributor.authorFORTINI, Ida
dc.contributor.authorGONCALVES, Marcia Rubia Rodrigues
dc.contributor.authorCOMERLATTI, Luiz Roberto
dc.contributor.authorCASTRO, Luiz Henrique Martins
dc.contributor.authorCALLEGARO, Dagoberto
dc.contributor.authorMONTEIRO, Mario Luiz Ribeiro
dc.date.accessioned2023-08-16T17:50:15Z
dc.date.available2023-08-16T17:50:15Z
dc.date.issued2023
dc.description.abstractBackground: Optic neuritis (ON), a major cause of visual impairment in young adults, is generally associated with rapid visual recovery when treated with intravenous methylprednisolone treatment (IVMPT). However, the optimal duration of such treatment is unknown, ranging from three to seven days in clinical practice. We aimed to compare the visual recovery in patients treated with 5-day or 7-day duration IVMPT.Methods: We performed a retrospective cohort study of consecutive patients with ON in Sa similar to o Paulo, Brazil, from 2016 to 2021. We compared the proportion of participants with visual impairment in 5-day and 7-day treatment schedules at discharge, at 1 month and between 6 and 12 months after the diagnosis of ON. The findings were adjusted to age, severity of the visual impairment, co-intervention with plasma exchange, time from symptom onset to IVMPT and the etiology of the ON to mitigate indication bias.Results: We included 73 patients with ON treated with 5 or 7-day duration of 1 g/d intravenous methylprednisolone therapy. Visual impairment at 6-12 months in the 5-day or the 7-day treatment groups was similar (57% x 59%, p > 0.9, Odds Ratio 1.03 [95% CI 0.59-1.84]). The results were similar after adjusting for prognostic variables and when observed at different time points.Conclusion: Visual recovery is similar in patients treated with 5-day and 7-day duration treatments of 1 g/day intravenous methylprednisolone, suggesting a ceiling effect. Limiting the duration of the treatment can reduce hospital stay and costs, without interfering with clinical benefit.eng
dc.description.indexMEDLINE
dc.description.indexPubMed
dc.description.indexWoS
dc.description.indexScopus
dc.identifier.citationMULTIPLE SCLEROSIS AND RELATED DISORDERS, v.75, article ID 104737, 5p, 2023
dc.identifier.doi10.1016/j.msard.2023.104737
dc.identifier.eissn2211-0356
dc.identifier.issn2211-0348
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/54711
dc.language.isoeng
dc.publisherELSEVIER SCI LTDeng
dc.relation.ispartofMultiple Sclerosis and Related Disorders
dc.rightsrestrictedAccesseng
dc.rights.holderCopyright ELSEVIER SCI LTDeng
dc.subject.wosClinical Neurologyeng
dc.titleA comparative study of visual outcome in patients with optic neuritis treated with five or seven days of intravenous corticosteroid treatmenteng
dc.typearticleeng
dc.type.categoryoriginal articleeng
dc.type.versionpublishedVersioneng
dspace.entity.typePublication
hcfmusp.citation.scopus0
hcfmusp.contributor.author-fmusphcGUILHERME DIOGO SILVA
hcfmusp.contributor.author-fmusphcSARA TERRIM
hcfmusp.contributor.author-fmusphcFERNANDO CAVALCANTI DE SA BENEVIDES FALCAO
hcfmusp.contributor.author-fmusphcMARIA ALICE PIMENTEL FALCAO
hcfmusp.contributor.author-fmusphcCLEUBER ESTEVES CHAVES
hcfmusp.contributor.author-fmusphcSAMIRA LUISA DOS APOSTOLOS PEREIRA
hcfmusp.contributor.author-fmusphcIDA FORTINI
hcfmusp.contributor.author-fmusphcMARCIA RUBIA RODRIGUES GONCALVES
hcfmusp.contributor.author-fmusphcLUIZ ROBERTO COMERLATTI
hcfmusp.contributor.author-fmusphcLUIZ HENRIQUE MARTINS CASTRO
hcfmusp.contributor.author-fmusphcDAGOBERTO CALLEGARO
hcfmusp.contributor.author-fmusphcMARIO LUIZ RIBEIRO MONTEIRO
hcfmusp.description.articlenumber104737
hcfmusp.description.volume75
hcfmusp.origemWOS
hcfmusp.origem.pubmed37156037
hcfmusp.origem.scopus2-s2.0-85156166604
hcfmusp.origem.wosWOS:001004181800001
hcfmusp.publisher.cityOXFORDeng
hcfmusp.publisher.countryENGLANDeng
hcfmusp.relation.referenceBECK RW, 1992, NEW ENGL J MED, V326, P581, DOI 10.1056/NEJM199202273260901eng
hcfmusp.relation.referenceButtgereit F, 2002, ANN RHEUM DIS, V61, P718, DOI 10.1136/ard.61.8.718eng
hcfmusp.relation.referenceCampana I.G., 2021, NEUROIMMUNOL REP, V1, DOI [10.1016/j.nerep.2021.100045.VolumeISSN, DOI 10.1016/J.NEREP.2021.100045.VOLUMEISSN]eng
hcfmusp.relation.referenceDucloyer JB, 2022, EUR J OPHTHALMOL, V32, P754, DOI 10.1177/11206721211028050eng
hcfmusp.relation.referenceLe Page E, 2016, LANCET, V387, P340eng
hcfmusp.relation.referenceLe Page E, 2015, LANCET, V386, P974, DOI 10.1016/S0140-6736(15)61137-0eng
hcfmusp.relation.referencePetzold A, 2014, NAT REV NEUROL, V10, P447, DOI 10.1038/nrneurol.2014.108eng
hcfmusp.relation.referenceSaitakis G, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23179769eng
hcfmusp.relation.referencevon Elm E, 2007, ANN INTERN MED, V147, P573, DOI 10.7326/0003-4819-147-8-200710160-00010eng
hcfmusp.scopus.lastupdate2024-04-12
relation.isAuthorOfPublication1c35fd18-495e-46bd-a6dd-f9e430c4818c
relation.isAuthorOfPublication9a257e80-933a-47c0-8d59-ff08b4c0b1a5
relation.isAuthorOfPublication0fd4d653-e381-4191-b4f9-833f47007517
relation.isAuthorOfPublication0818269a-1ce9-4491-a852-467e015b1d91
relation.isAuthorOfPublication1fc50978-68fd-414e-a0ad-e885e178c0e8
relation.isAuthorOfPublication56762958-32b0-4f44-aa16-c4447290209b
relation.isAuthorOfPublication4b374ea5-9777-43fc-9a72-e597922ede7a
relation.isAuthorOfPublication0421762c-8920-43d0-88a3-02e73d5c0ee9
relation.isAuthorOfPublicatione29f6515-ebb2-456a-b838-dff28b73528e
relation.isAuthorOfPublicationbcac774d-12b8-4192-b2d9-20bdfcc749af
relation.isAuthorOfPublicationd4c82f1a-7fad-4f17-a653-10dd769f21bc
relation.isAuthorOfPublication49360274-203b-489e-a263-d0aba4cb5be3
relation.isAuthorOfPublication.latestForDiscovery1c35fd18-495e-46bd-a6dd-f9e430c4818c
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Nenhuma Miniatura disponível
Nome:
art_SILVA_A_comparative_study_of_visual_outcome_in_patients_2023.PDF
Tamanho:
526.45 KB
Formato:
Adobe Portable Document Format
Descrição:
publishedVersion (English)
Baixar
Coleções
Artigos e Materiais de Revistas Científicas - FM/MNE
Artigos e Materiais de Revistas Científicas - FM/MOF
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - HC/InRad
Artigos e Materiais de Revistas Científicas - LIM/33
Carregar mais